Chardan Capital Raises Krystal Biotech (NASDAQ:KRYS) Price Target to $218.00

Krystal Biotech (NASDAQ:KRYS) had its price objective increased by Chardan Capital from $212.00 to $218.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s price objective indicates a potential upside of 16.04% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday. Citigroup increased their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $210.00.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $187.86 on Thursday. Krystal Biotech has a 1 year low of $107.50 and a 1 year high of $219.34. The firm has a 50 day moving average price of $157.37 and a 200 day moving average price of $175.23. The company has a market cap of $5.40 billion, a price-to-earnings ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same period in the previous year, the firm earned $0.30 earnings per share. Krystal Biotech’s revenue for the quarter was up 116.4% on a year-over-year basis. Sell-side analysts predict that Krystal Biotech will post 6.14 EPS for the current year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Large investors have recently modified their holdings of the company. Summit Trail Advisors LLC acquired a new stake in shares of Krystal Biotech in the 3rd quarter worth about $1,893,000. Entropy Technologies LP acquired a new stake in shares of Krystal Biotech in the 4th quarter worth about $548,000. Swiss National Bank increased its holdings in shares of Krystal Biotech by 8.0% in the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after acquiring an additional 2,900 shares during the period. Janney Montgomery Scott LLC increased its stake in Krystal Biotech by 42.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock valued at $8,239,000 after buying an additional 15,545 shares during the period. Finally, Citigroup Inc. increased its stake in Krystal Biotech by 65.4% during the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after buying an additional 13,874 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).